US20120209144A1 - Systems and methods for applying a selected treatment agent into contact with tissue - Google Patents
Systems and methods for applying a selected treatment agent into contact with tissue Download PDFInfo
- Publication number
- US20120209144A1 US20120209144A1 US13/454,842 US201213454842A US2012209144A1 US 20120209144 A1 US20120209144 A1 US 20120209144A1 US 201213454842 A US201213454842 A US 201213454842A US 2012209144 A1 US2012209144 A1 US 2012209144A1
- Authority
- US
- United States
- Prior art keywords
- tissue
- treatment agent
- treatment
- systems
- cytokine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B18/1492—Probes or electrodes therefor having a flexible, catheter-like structure, e.g. for heart ablation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B18/1477—Needle-like probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00214—Expandable means emitting energy, e.g. by elements carried thereon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00214—Expandable means emitting energy, e.g. by elements carried thereon
- A61B2018/0022—Balloons
- A61B2018/00232—Balloons having an irregular shape
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00553—Sphincter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00636—Sensing and controlling the application of energy
- A61B2018/00773—Sensed parameters
- A61B2018/00791—Temperature
- A61B2018/00797—Temperature measured by multiple temperature sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00636—Sensing and controlling the application of energy
- A61B2018/00773—Sensed parameters
- A61B2018/00791—Temperature
- A61B2018/00815—Temperature measured by a thermistor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B2018/1405—Electrodes having a specific shape
- A61B2018/1425—Needle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0082—Catheter tip comprising a tool
- A61M25/0084—Catheter tip comprising a tool being one or more injection needles
Definitions
- the invention is directed to systems and methods for treating interior tissue regions of the body. More specifically, the invention is directed to systems and methods for treating dysfunctions of organs and tissue in the gastrointestinal tract.
- Disorders of organs or tissue of the gastrointestinal tract can be caused by as neurological factors (such as abnormal nerve impulses) or by physical factors (such as excess tissue volume).
- intestinal motility i.e., the contraction of intestinal muscles and the propulsion and movement of the lumenal contents
- nerves and hormones as well as by electrical activity in the muscular wall of the intestine.
- electrical activity in the muscular wall of the intestine There are several disorders that involve abnormal motility and result in abnormal and uncomfortable visceral sensations. These disorders can cause significant discomfort and distress in the absence of gross physical abnormality of the intestine.
- IBS irritable bowel syndrome
- IBS can lead to crampy pain, gassiness, bloating, and changes in bowel habits.
- Some people with IBS have constipation (difficult or infrequent bowel movements) others have diarrhea (frequent loose stools, often with an urgent need to move the bowels); and some people experience both symptoms intermittently.
- the person with IBS has a crampy urge to move the bowels, but cannot do so.
- the cause of IBS is not known, and as yet there is no cure.
- IBS can be characterized as a functional disorder because there is no sign of disease when the intestine is examined, often IBS is just a mild annoyance, but for some people it can be disabling.
- Dyspepsia is another example. Dyspepsia is literally translated as ‘bad digestion” and is commonly known as indigestion. Motility-like dyspepsia causes persistent or recurring abdominal pain that is centered in the upper abdomen. People with motility associated dyspepsia also may experience bloating, nausea, burping and a feeling of fullness that occurs soon after eating. It is an extremely common symptom complex, affecting as much as one-fourth of the United States adult population.
- One aspect of the invention provides a method of treating tissue within a body.
- the method comprises selecting at least one treatment agent comprising at least one of a vanilloid compound and a cytokine compound.
- the method provides a source of the treatment agent.
- the method includes deploying through the interior lumen of the endoscope a catheter carrying on its distal end a tissue-piercing element adjacent to the targeted tissue region.
- the method includes coupling the catheter to the source of the treatment agent, and applying through the tissue-piercing element the treatment agent into contact with the targeted tissue region.
- the method injects the treatment agent into subsurface tissue in the targeted tissue region.
- the method includes providing a guide wire to facilitate deployment of the catheter.
- FIGS. 1A and 1B are schematic views of a system for treating tissue that includes a treatment device with a tissue piercing member that embodies features of the invention, FIG. 1A showing the treatment device deployed in a tissue region and FIG. 1B showing the treatment device piercing the tissue region to inject a treatment agent;
- FIGS. 2A and 2B are schematic views of a system for treating tissue that includes a treatment device with multiple tissue piercing members that embodies features of the invention, FIG. 2A showing the treatment device deployed in a tissue region and FIG. 2B showing the treatment device piercing the tissue region to inject a treatment agent;
- FIG. 3 is an embodiment of a tissue treatment device that takes the form of a syringe and a needle for injecting a treatment agent into a tissue region that can be visualized from outside the body;
- FIG. 4 is an embodiment of a tissue treatment device for injecting a treatment agent into a tissue region that cannot be visualized from outside the body.
- This Specification discloses various systems and methods for treating dysfunctions of organs or tissue in the gastrointestinal tract. Still, it should be appreciated that the disclosed systems and methods are applicable for use in treating other dysfunctions elsewhere in the body, e.g., for treating sphincter barrier dysfunctions in the lower gastrointestinal tract or in the upper gastrointestinal tract.
- the systems and methods that embody features of the invention are adaptable for use with catheter-based systems and surgical techniques, as well as systems and surgical Techniques that are not necessarily catheter-based.
- FIGS. 1A and 1B A tissue treatment system 10 that embodies features of the invention is shown in FIGS. 1A and 1B .
- the tissue treatment system 10 includes a tissue treatment device 12 and an apparatus 14 to deliver the tissue treatment device 12 to a tissue region 16 targeted for treatment.
- the treatment system 10 also includes a source 18 of a treatment agent 20 .
- the tissue treatment device 12 serves to apply the treatment agent 20 to the targeted tissue region 16 to obtain a desired therapeutic effect.
- the therapeutic effect can comprise either alteration of nerve impulse pathways in the region 16 or a physical alteration of tissue characteristics in the region 16 .
- the tissue treatment device 12 includes one or more agent delivery ports 22 .
- the one or more delivery ports 22 can apply the treatment agent 20 to surface tissue in the region 16 .
- the port 20 is located at the end of a tissue piercing member 24 .
- the treatment agent 20 may be injected into subsurface tissue.
- the tissue treatment device 12 can include single or multiple ports 22 located single or multiple tissue piercing members 24 to inject the treatment agent 20 .
- a single tissue piercing member 24 (with a single port 22 ) may be used.
- the treatment device 24 can carry multiple tissue piercing members 24 , each with a port 22 .
- the multiple tissue piercing members 24 are arranged in a spaced-apart array, to apply the treatment agent 20 in a prescribed pattern at the targeted site.
- the tissue treatment device 12 may employ air powered, needle-less injection technology.
- the configuration of the delivery apparatus 14 for the device 12 can also vary, depending upon the accessibility of the treatment site and the particular treatment objectives desired. If the treatment site can be directly visualized the delivery apparatus 14 , the source 18 , and the treatment device 12 can comprise a syringe 100 and a needle 102 , as FIG. 3 shows.
- the delivery apparatus 14 can comprise an endoscope 106 having an interior lumen 104 passed down the esophagus through the mouth, as FIG. 4 shows.
- the treatment device 12 is desirably carried on the distal end of a catheter tube 108 for passage through the endoscope lumen 104 to the targeted site.
- a guidewire may be used, if desired, to further facilitate deployment of the endoscope and treatment device to the targeted site.
- the treatment agent 20 is selected from a group of candidate agents based upon the physiologic effect or effects that are desired.
- One or more candidate agents may be applied, either as a primary treatment modality, a neoadjuvent treatment modality, or an adjuvent treatment modality.
- the group consists essentially of two candidate agents: (1) Vanilloid Compounds, and (2) Cytokine Sub-Types.
- the treatment agent 20 can comprise a vanilloid compound.
- Vanilloid compounds have a unique capacity to bind to a membrane receptor in sensory neurons.
- Capsaicin is one of many vanilloid compounds.
- Capsaicin is a powerful basic compound which is derived from chili peppers.
- VR 1 The specific neuron for capsaicin is deemed “VR 1 ”. This receptor is expressed only on small unmyelinated C-fibers (nerves typically involved in special visceral sensation and pain).
- vanilloid compound as used herein means a compound or a mixture of compounds having a biologically active vanillyl group.
- vanilloid compounds include both naturally occurring vanilloids, synthetic vanilloids, pharmaceutically acceptable salts of the vanilloid compound (whether natural or synthetic) as well as pharmaceutically acceptable derivatives and/or analogues thereof (whether natural or synthetic).
- natural vanilloid compounds include both the crude extracts and the purified extracts of active vanilloid compounds from: capsicum, cayenne pepper, black pepper, paprika, cinnamon, clove, mace, mustard, ginger, turmeric, papaya seed and the cactus-like plant Euphorbia resinifera.
- Synthetic vanilloid compounds such as synthetic capsaicin are disclosed in WO 96/40079, which is incorporated herein by reference.
- the vanilloid compound family includes: Capsaicin; Dihydrocapsaicin: Nordihydrocapsaicin; Homocapsaicin: Homodihydrocapsaicin.
- resiniferotoxin (RTX) is derived from the euphorbia cactus and is considered a capsaicin-like compound. This substance also activates the VR 1 receptor and attenuates or eliminates afferent nerve function, although it may not illicit the rapid heat sensation that other vanilloids produce.
- vanilloid compounds include capsaicin ((E)-(N)-[(4-hydroxy-3-methoxyphenyl)-methyl]-8-methyl-6-nonenamide); eugenol (2-methoxy-4-(2-propenyl)phenol);zingerone (4-(4-hydroxy-3-methoxyphenyl)-2-butanone); curcumin (1,7-bis (4-hydroxy-3-methoxyphenyl)-1, 6-heptadiene-3, 5-dione); piperine (1-[5-(1,3-benzodioxol-5-yl)-1-oxo-2,4-pentadienyl] piperidine); resiniferatoxin(6, 7-deepoxy-6, 7-didehydro-5-deoxy-21-dephenyl-21-(phenylmethyl)-20-(4-hydroxy-3-thoxybenzeneacetate)) or pharmaceutically effective salts, analogues, derivatives or equivalents thereof.
- the treatment agent 20 can include capsaicin, another vanilloid compound, RTX, or combination thereof, alone or in combination with other substances (which will be generically called a vanilloid-containing treatment agent 20 ).
- the vanilloid-containing treatment agent can be applied through the port 22 or ports 22 to the mucosal lining or extrinsically to the outside of an organ.
- the vanilloid-containing treatment agent can also be injected into the targeted tissue region or organ wall.
- the treatment agent 20 can be a solution, a gel, a powder, a pellet, or other form.
- the treatment agent may be released immediately, or, be a sustained release product such as a slow released implant, slow release gel, coated pellet, microsphere, or other form.
- the vanilloid-containing treatment agent 20 may be applied or injected as primary therapy, or, as a neoadjuvant or adjuvant procedure.
- RF energy may be used to incite a wound, followed by application of the vanilloid-containing treatment agent to facilitate exuberant wound healing.
- a vanilloid-containing treatment agent can serve to diminish the pain impulses or could attenuate the dysmotility and alleviate the disease state.
- vanilloid materials that can be used is produced by Afferon and is called RTX, which has been instilled into the lumen of the urinary bladder for the treatment of urge incontinence.
- RTX vanilloid material produced by Afferon and is called RTX, which has been instilled into the lumen of the urinary bladder for the treatment of urge incontinence.
- topical, over-the-counter capsaicin products for topical analgesic applications.
- the treatment agent 20 can include one or more subtypes of cytokines.
- a cytokine in the natural state within the body, is a protein produced and released by a biological cell that has an effect on the local environment surrounding the cell. Cytokines are involved in many cellular processes, such as wound healing. The mechanism of action would depend on the specific cytokine utilized.
- cytokine subtype means any polypeptide that affects the functions of other cells, and is a molecule which modulates interactions between cells in the immune or inflammatory response.
- a cytokine subtype includes, but is not limited to monokines and lymphokines regardless of which cells produce them.
- a monokine is generally referred to as being produced and secreted by a mononuclear cell, such as a macrophage and/or monocyte but many other cells produce monokines, such as natural killer cells, fibroblasts, basophils, neutrophils, endothelial cells, brain astrocytes, bone marrow stromal cells, epideral keratinocytes, and B- lymphocytes.
- Lymphokines are generally referred to as being produced by lymphocyte cells.
- cytokine subtypes include, but are not limited to, interleukin-1. (IL-1), tumor necrosis factor-alpha (TNF alpha) and tumor necrosis factor beta (TNF beta).
- IL-1 interleukin-1
- TNF alpha tumor necrosis factor-alpha
- TNF beta tumor necrosis factor beta
- cytokine subtypes include TGF- ⁇ (transforming growth factor ⁇ ); PDGF (platelet derived growth factor) b-FGF (basic fibroblast growth factor): IGF-1 (insulin-like growth factor 1); EGF (epidermal growth factor); and VEGF.
- TGF- ⁇ transforming growth factor ⁇
- PDGF platelet derived growth factor
- b-FGF basic fibroblast growth factor
- IGF-1 insulin-like growth factor 1
- EGF epidermal growth factor
- VEGF vascular endothelial growth factor
- the effects of a given cytokine upon tissue physiology can include one or more of the following: smooth muscle and fibroblast mitogenic effects (induces division and growth of cells); stimulation of the release of cytokines from other cells; chemoattractant (bringing new healing cells into local region); decrease of collagen enzyme activity allowing collagen to build up; inflammation; and angiogenesis (development of new blood vessels).
- the treatment agent 20 can include a cytokine sub-type or combination of cytokine sub-types, alone or in combination with other substances.
- the cytokine-containing treatment agent can be applied by the port or ports 22 to the tissue or organ wall, or injected into the tissue or organ wall.
- the cytokine-containing treatment agent 20 can be a solution, a gel, a powder, a pellet, or other form.
- the treatment agent may be released immediately, or, be a sustained release product such as a slow released implant, slow release gel, coated pellet, microsphere, or other form.
- the cytokine-containing agent 20 may be applied or injected as primary therapy, or, as a neoadjuvant or adjuvant procedure.
- RF radio frequency
- cytokines can serve to initiate the process of healing within the local region. This process includes, but is not limited to, influx of white blood cells and macrophages, stimulation of fibroblast and smooth muscle division and collagen secretion, new blood vessel growth, wound contraction and tightening, maturation of the new or existing collagen framework, and reduced tissue compliance. These tissue effects could improve the compliance and reduce the tissue volume.
- cytokine materials examples include commercially available Regranex, which is recombinant human PDGF-BB. This material has been applied as a gel for promoting the healing of diabetic foot ulcers. Platelet granules contain many of the cytokines listed above, and the cytokines can be extracted with a fairly simple technique (platelet releasates). Platelets (harvested as a pooled platelet product or from autologous donation) provide a source of cytokines for extraction. TGF- ⁇ and PDGF are considered to be the most important substances for the purpose of initiating the wound healing process.
Abstract
Systems and methods that treat disorders of the gastrointestinal tract by applying one or more treatment agents to tissue at or near the region where abnormal neurological symptoms or abnormal tissue conditions exist. The treatment agent is selected to either disrupt the abnormal nerve pathways and/or to alleviate the abnormal tissue conditions. The treatment agent can include at least one cytokine and/or at least one vanilloid compound to evoke a desired tissue response. The systems and methods can be used a primary treatment modality, or as a neoadjuvent or adjuvant treatment modality.
Description
- This application is a continuation of co-pending U.S. patent application Ser. No. 11/906,457, filed Oct. 2, 2007, which is a divisional of U.S. patent application Ser. No. 10/912,268, filed Aug. 5, 2004 (now U.S. Pat. No. 7,293,563), which is divisional of U.S. patent application Ser. No. 09/994,375, filed Nov. 26, 2001 (now U.S. Pat. 6,790,207), which is a continuation-in-part of U.S. patent application Ser. No. 09/304,737, filed May 4, 1999 (now U.S. Pat. No. 6,464,697), and a continuation-in-part of U.S. patent application Ser. No. 09/090,794, filed Jun. 4, 1998 (now abandoned).
- In a general sense, the invention is directed to systems and methods for treating interior tissue regions of the body. More specifically, the invention is directed to systems and methods for treating dysfunctions of organs and tissue in the gastrointestinal tract.
- Disorders of organs or tissue of the gastrointestinal tract can be caused by as neurological factors (such as abnormal nerve impulses) or by physical factors (such as excess tissue volume).
- For example, intestinal motility (i.e., the contraction of intestinal muscles and the propulsion and movement of the lumenal contents) is controlled by nerves and hormones, as well as by electrical activity in the muscular wall of the intestine. There are several disorders that involve abnormal motility and result in abnormal and uncomfortable visceral sensations. These disorders can cause significant discomfort and distress in the absence of gross physical abnormality of the intestine.
- For example, irritable bowel syndrome (IBS) is a common disorder of the intestines. IBS can lead to crampy pain, gassiness, bloating, and changes in bowel habits. Some people with IBS have constipation (difficult or infrequent bowel movements) others have diarrhea (frequent loose stools, often with an urgent need to move the bowels); and some people experience both symptoms intermittently. Sometimes the person with IBS has a crampy urge to move the bowels, but cannot do so. The cause of IBS is not known, and as yet there is no cure. IBS can be characterized as a functional disorder because there is no sign of disease when the intestine is examined, often IBS is just a mild annoyance, but for some people it can be disabling.
- Dyspepsia is another example. Dyspepsia is literally translated as ‘bad digestion” and is commonly known as indigestion. Motility-like dyspepsia causes persistent or recurring abdominal pain that is centered in the upper abdomen. People with motility associated dyspepsia also may experience bloating, nausea, burping and a feeling of fullness that occurs soon after eating. It is an extremely common symptom complex, affecting as much as one-fourth of the United States adult population.
- There are other disorders affecting the gastrointestinal tract that are characterized by abnormal tissue conditions not associated with neural abnormalities.
- One aspect of the invention provides a method of treating tissue within a body. The method comprises selecting at least one treatment agent comprising at least one of a vanilloid compound and a cytokine compound. The method provides a source of the treatment agent. The method includes deploying through the interior lumen of the endoscope a catheter carrying on its distal end a tissue-piercing element adjacent to the targeted tissue region. The method includes coupling the catheter to the source of the treatment agent, and applying through the tissue-piercing element the treatment agent into contact with the targeted tissue region.
- In one embodiment, the method injects the treatment agent into subsurface tissue in the targeted tissue region.
- In one embodiment, the method includes providing a guide wire to facilitate deployment of the catheter.
- Features and advantages of the inventions are set forth in the following Description and Drawings, as well as in the appended Claims.
-
FIGS. 1A and 1B are schematic views of a system for treating tissue that includes a treatment device with a tissue piercing member that embodies features of the invention,FIG. 1A showing the treatment device deployed in a tissue region andFIG. 1B showing the treatment device piercing the tissue region to inject a treatment agent; -
FIGS. 2A and 2B are schematic views of a system for treating tissue that includes a treatment device with multiple tissue piercing members that embodies features of the invention,FIG. 2A showing the treatment device deployed in a tissue region andFIG. 2B showing the treatment device piercing the tissue region to inject a treatment agent; -
FIG. 3 is an embodiment of a tissue treatment device that takes the form of a syringe and a needle for injecting a treatment agent into a tissue region that can be visualized from outside the body; and -
FIG. 4 is an embodiment of a tissue treatment device for injecting a treatment agent into a tissue region that cannot be visualized from outside the body. - The invention may be embodied in several forms without departing from its spirit or essential characteristics. The scope of the invention is defined in the appended claims, rather than in the specific description preceding them. All embodiments that fall within the meaning and range of equivalency of the claims are therefore intended to be embraced by the claims.
- This Specification discloses various systems and methods for treating dysfunctions of organs or tissue in the gastrointestinal tract. Still, it should be appreciated that the disclosed systems and methods are applicable for use in treating other dysfunctions elsewhere in the body, e.g., for treating sphincter barrier dysfunctions in the lower gastrointestinal tract or in the upper gastrointestinal tract. The systems and methods that embody features of the invention are adaptable for use with catheter-based systems and surgical techniques, as well as systems and surgical Techniques that are not necessarily catheter-based.
- A tissue treatment system 10 that embodies features of the invention is shown in
FIGS. 1A and 1B . The tissue treatment system 10 includes atissue treatment device 12 and an apparatus 14 to deliver thetissue treatment device 12 to atissue region 16 targeted for treatment. - The treatment system 10 also includes a
source 18 of atreatment agent 20. - The
tissue treatment device 12 serves to apply thetreatment agent 20 to the targetedtissue region 16 to obtain a desired therapeutic effect. The therapeutic effect can comprise either alteration of nerve impulse pathways in theregion 16 or a physical alteration of tissue characteristics in theregion 16. - The
tissue treatment device 12 includes one or moreagent delivery ports 22. The one ormore delivery ports 22 can apply thetreatment agent 20 to surface tissue in theregion 16. Desirably (asFIG. 1A shows), theport 20 is located at the end of atissue piercing member 24. In this arrangement, thetreatment agent 20 may be injected into subsurface tissue. - The
tissue treatment device 12 can include single ormultiple ports 22 located single or multipletissue piercing members 24 to inject thetreatment agent 20. AsFIGS. 1A and 1B show, a single tissue piercing member 24 (with a single port 22) may be used. Alternatively, asFIGS. 2A and 2B show, thetreatment device 24 can carry multipletissue piercing members 24, each with aport 22. Desirably, the multipletissue piercing members 24 are arranged in a spaced-apart array, to apply thetreatment agent 20 in a prescribed pattern at the targeted site. - Alternatively, the
tissue treatment device 12 may employ air powered, needle-less injection technology. - The configuration of the delivery apparatus 14 for the
device 12 can also vary, depending upon the accessibility of the treatment site and the particular treatment objectives desired. If the treatment site can be directly visualized the delivery apparatus 14, thesource 18, and thetreatment device 12 can comprise a syringe 100 and aneedle 102, asFIG. 3 shows. - If the treatment site can not be directly visualized or is otherwise not as readily accessible, the delivery apparatus 14 can comprise an
endoscope 106 having aninterior lumen 104 passed down the esophagus through the mouth, asFIG. 4 shows. In this arrangement, thetreatment device 12 is desirably carried on the distal end of acatheter tube 108 for passage through theendoscope lumen 104 to the targeted site. A guidewire may be used, if desired, to further facilitate deployment of the endoscope and treatment device to the targeted site. - The
treatment agent 20 is selected from a group of candidate agents based upon the physiologic effect or effects that are desired. One or more candidate agents may be applied, either as a primary treatment modality, a neoadjuvent treatment modality, or an adjuvent treatment modality. - In the illustrated embodiment, the group consists essentially of two candidate agents: (1) Vanilloid Compounds, and (2) Cytokine Sub-Types.
- The
treatment agent 20 can comprise a vanilloid compound. Vanilloid compounds have a unique capacity to bind to a membrane receptor in sensory neurons. Capsaicin is one of many vanilloid compounds. Capsaicin is a powerful basic compound which is derived from chili peppers. - The specific neuron for capsaicin is deemed “VR1”. This receptor is expressed only on small unmyelinated C-fibers (nerves typically involved in special visceral sensation and pain).
- Exposure to vanilloid compounds variably reduces the responsiveness of the neuron to stimuli. In many cases, the neuron may actually degenerate either temporarily or permanently, thus impairing transmission of pain signals or other special sensory signals.
- The term “vanilloid compound” as used herein means a compound or a mixture of compounds having a biologically active vanillyl group. vanilloid compounds include both naturally occurring vanilloids, synthetic vanilloids, pharmaceutically acceptable salts of the vanilloid compound (whether natural or synthetic) as well as pharmaceutically acceptable derivatives and/or analogues thereof (whether natural or synthetic). Examples of natural vanilloid compounds include both the crude extracts and the purified extracts of active vanilloid compounds from: capsicum, cayenne pepper, black pepper, paprika, cinnamon, clove, mace, mustard, ginger, turmeric, papaya seed and the cactus-like plant Euphorbia resinifera.
- Synthetic vanilloid compounds such as synthetic capsaicin are disclosed in WO 96/40079, which is incorporated herein by reference. The vanilloid compound family includes: Capsaicin; Dihydrocapsaicin: Nordihydrocapsaicin; Homocapsaicin: Homodihydrocapsaicin. Alternatively, resiniferotoxin (RTX) is derived from the euphorbia cactus and is considered a capsaicin-like compound. This substance also activates the VR1 receptor and attenuates or eliminates afferent nerve function, although it may not illicit the rapid heat sensation that other vanilloids produce.
- Other examples of vanilloid compounds include capsaicin ((E)-(N)-[(4-hydroxy-3-methoxyphenyl)-methyl]-8-methyl-6-nonenamide); eugenol (2-methoxy-4-(2-propenyl)phenol);zingerone (4-(4-hydroxy-3-methoxyphenyl)-2-butanone); curcumin (1,7-bis (4-hydroxy-3-methoxyphenyl)-1, 6-heptadiene-3, 5-dione); piperine (1-[5-(1,3-benzodioxol-5-yl)-1-oxo-2,4-pentadienyl] piperidine); resiniferatoxin(6, 7-deepoxy-6, 7-didehydro-5-deoxy-21-dephenyl-21-(phenylmethyl)-20-(4-hydroxy-3-thoxybenzeneacetate)) or pharmaceutically effective salts, analogues, derivatives or equivalents thereof.
- The
treatment agent 20 can include capsaicin, another vanilloid compound, RTX, or combination thereof, alone or in combination with other substances (which will be generically called a vanilloid-containing treatment agent 20). - The vanilloid-containing treatment agent can be applied through the
port 22 orports 22 to the mucosal lining or extrinsically to the outside of an organ. The vanilloid-containing treatment agent can also be injected into the targeted tissue region or organ wall. - The
treatment agent 20 can be a solution, a gel, a powder, a pellet, or other form. The treatment agent may be released immediately, or, be a sustained release product such as a slow released implant, slow release gel, coated pellet, microsphere, or other form. - The vanilloid-containing
treatment agent 20 may be applied or injected as primary therapy, or, as a neoadjuvant or adjuvant procedure. For example, RF energy may be used to incite a wound, followed by application of the vanilloid-containing treatment agent to facilitate exuberant wound healing. - In dyspepsia and irritable bowel syndrome, the use of a vanilloid-containing treatment agent can serve to diminish the pain impulses or could attenuate the dysmotility and alleviate the disease state.
- An example of vanilloid materials that can be used is produced by Afferon and is called RTX, which has been instilled into the lumen of the urinary bladder for the treatment of urge incontinence. There are also several topical, over-the-counter capsaicin products for topical analgesic applications.
- The
treatment agent 20 can include one or more subtypes of cytokines. A cytokine, in the natural state within the body, is a protein produced and released by a biological cell that has an effect on the local environment surrounding the cell. Cytokines are involved in many cellular processes, such as wound healing. The mechanism of action would depend on the specific cytokine utilized. - The term “cytokine subtype” as used herein means any polypeptide that affects the functions of other cells, and is a molecule which modulates interactions between cells in the immune or inflammatory response. A cytokine subtype includes, but is not limited to monokines and lymphokines regardless of which cells produce them. For instance, a monokine is generally referred to as being produced and secreted by a mononuclear cell, such as a macrophage and/or monocyte but many other cells produce monokines, such as natural killer cells, fibroblasts, basophils, neutrophils, endothelial cells, brain astrocytes, bone marrow stromal cells, epideral keratinocytes, and B- lymphocytes. Lymphokines are generally referred to as being produced by lymphocyte cells. Examples of cytokine subtypes include, but are not limited to, interleukin-1. (IL-1), tumor necrosis factor-alpha (TNF alpha) and tumor necrosis factor beta (TNF beta).
- Other cytokine subtypes include TGF-β (transforming growth factor β); PDGF (platelet derived growth factor) b-FGF (basic fibroblast growth factor): IGF-1 (insulin-like growth factor 1); EGF (epidermal growth factor); and VEGF. Some of these cytokines are available commercially, could be produced commercially, or can be extracted from a persons harvested platelets (platelet releasates). The effects of a given cytokine upon tissue physiology can include one or more of the following: smooth muscle and fibroblast mitogenic effects (induces division and growth of cells); stimulation of the release of cytokines from other cells; chemoattractant (bringing new healing cells into local region); decrease of collagen enzyme activity allowing collagen to build up; inflammation; and angiogenesis (development of new blood vessels).
- The
treatment agent 20 can include a cytokine sub-type or combination of cytokine sub-types, alone or in combination with other substances. The cytokine-containing treatment agent can be applied by the port orports 22 to the tissue or organ wall, or injected into the tissue or organ wall. - The cytokine-containing
treatment agent 20 can be a solution, a gel, a powder, a pellet, or other form. The treatment agent may be released immediately, or, be a sustained release product such as a slow released implant, slow release gel, coated pellet, microsphere, or other form. - The cytokine-containing
agent 20 may be applied or injected as primary therapy, or, as a neoadjuvant or adjuvant procedure. For example, radio frequency (RF) energy may be used to induce the wound healing process, followed by cytokine application to facilitate more exuberant wound healing. - The application of a single cytokine or mixture thereof, as primary, neoadjuvant, or adjuvant therapy for abnormal tissue conditions (e.g., excess tissue volume) could have the various mechanical and therapeutic effects. With or without an inciting wound event (such as RF), cytokines can serve to initiate the process of healing within the local region. This process includes, but is not limited to, influx of white blood cells and macrophages, stimulation of fibroblast and smooth muscle division and collagen secretion, new blood vessel growth, wound contraction and tightening, maturation of the new or existing collagen framework, and reduced tissue compliance. These tissue effects could improve the compliance and reduce the tissue volume.
- Examples of cytokine materials that can be used include commercially available Regranex, which is recombinant human PDGF-BB. This material has been applied as a gel for promoting the healing of diabetic foot ulcers. Platelet granules contain many of the cytokines listed above, and the cytokines can be extracted with a fairly simple technique (platelet releasates). Platelets (harvested as a pooled platelet product or from autologous donation) provide a source of cytokines for extraction. TGF-β and PDGF are considered to be the most important substances for the purpose of initiating the wound healing process.
- Various features of the invention are set forth in the following claims.
Claims (3)
1. A method of treating tissue within a body comprising
selecting at least one treatment agent comprising at least one of a vanilloid compound and a cytokine compound,
providing a source of the treatment agent,
deploying through the interior lumen of the endoscope a catheter carrying on its distal end a tissue-piercing element adjacent to a targeted tissue region,
coupling the catheter to the source of the treatment agent, and
applying through the tissue-piercing element the treatment agent into contact with the targeted tissue region.
2. A method according to claim 1
wherein the applying includes injecting the treatment agent into subsurface tissue in the targeted tissue region.
3. A method according to claim 1
further including providing a guide wire to facilitate deployment of the catheter.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/454,842 US20120209144A1 (en) | 1998-06-04 | 2012-04-24 | Systems and methods for applying a selected treatment agent into contact with tissue |
US13/679,785 US20130072750A1 (en) | 1998-02-19 | 2012-11-16 | Systems and methods for treating obesity and other gastrointestinal conditions |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9079498A | 1998-06-04 | 1998-06-04 | |
US09/304,737 US6464697B1 (en) | 1998-02-19 | 1999-05-04 | Stomach and adjoining tissue regions in the esophagus |
US09/994,375 US6790207B2 (en) | 1998-06-04 | 2001-11-26 | Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract |
US10/912,268 US7293563B2 (en) | 1998-06-04 | 2004-08-05 | Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract |
US11/906,457 US8161976B2 (en) | 1998-06-04 | 2007-10-02 | Systems and methods for applying a selected treatment agent into contact with tissue |
US13/454,842 US20120209144A1 (en) | 1998-06-04 | 2012-04-24 | Systems and methods for applying a selected treatment agent into contact with tissue |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/906,457 Continuation US8161976B2 (en) | 1998-02-19 | 2007-10-02 | Systems and methods for applying a selected treatment agent into contact with tissue |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/410,448 Continuation-In-Part US6405732B1 (en) | 1994-06-24 | 1999-10-01 | Method to treat gastric reflux via the detection and ablation of gastro-esophageal nerves and receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120209144A1 true US20120209144A1 (en) | 2012-08-16 |
Family
ID=33568440
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/994,375 Expired - Lifetime US6790207B2 (en) | 1998-02-19 | 2001-11-26 | Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract |
US10/912,268 Expired - Fee Related US7293563B2 (en) | 1998-02-19 | 2004-08-05 | Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract |
US11/906,457 Expired - Fee Related US8161976B2 (en) | 1998-02-19 | 2007-10-02 | Systems and methods for applying a selected treatment agent into contact with tissue |
US13/454,842 Abandoned US20120209144A1 (en) | 1998-02-19 | 2012-04-24 | Systems and methods for applying a selected treatment agent into contact with tissue |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/994,375 Expired - Lifetime US6790207B2 (en) | 1998-02-19 | 2001-11-26 | Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract |
US10/912,268 Expired - Fee Related US7293563B2 (en) | 1998-02-19 | 2004-08-05 | Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract |
US11/906,457 Expired - Fee Related US8161976B2 (en) | 1998-02-19 | 2007-10-02 | Systems and methods for applying a selected treatment agent into contact with tissue |
Country Status (1)
Country | Link |
---|---|
US (4) | US6790207B2 (en) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6733495B1 (en) | 1999-09-08 | 2004-05-11 | Curon Medical, Inc. | Systems and methods for monitoring and controlling use of medical devices |
US9023031B2 (en) | 1997-08-13 | 2015-05-05 | Verathon Inc. | Noninvasive devices, methods, and systems for modifying tissues |
US7468060B2 (en) * | 1998-02-19 | 2008-12-23 | Respiratory Diagnostic, Inc. | Systems and methods for treating obesity and other gastrointestinal conditions |
US6790207B2 (en) * | 1998-06-04 | 2004-09-14 | Curon Medical, Inc. | Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract |
WO1999055245A1 (en) | 1998-04-30 | 1999-11-04 | Edwards Stuart D | Electrosurgical sphincter treatment apparatus |
US6740082B2 (en) | 1998-12-29 | 2004-05-25 | John H. Shadduck | Surgical instruments for treating gastro-esophageal reflux |
WO2000069376A1 (en) * | 1999-05-18 | 2000-11-23 | Silhouette Medical Inc. | Surgical weight control device |
AU7352500A (en) | 1999-09-08 | 2001-04-10 | Curon Medical, Inc. | Systems and methods for monitoring and controlling use of medical devices |
CA2384025A1 (en) | 1999-09-08 | 2001-03-15 | Curon Medical, Inc. | System for controlling a family of treatment devices |
US20040215235A1 (en) | 1999-11-16 | 2004-10-28 | Barrx, Inc. | Methods and systems for determining physiologic characteristics for treatment of the esophagus |
CA2388861C (en) | 1999-11-16 | 2013-09-03 | Robert A. Ganz | System and method of treating abnormal tissue in the human esophagus |
US20060095032A1 (en) | 1999-11-16 | 2006-05-04 | Jerome Jackson | Methods and systems for determining physiologic characteristics for treatment of the esophagus |
US8845632B2 (en) | 2000-05-18 | 2014-09-30 | Mederi Therapeutics, Inc. | Graphical user interface for monitoring and controlling use of medical devices |
US20060258562A1 (en) * | 2000-07-31 | 2006-11-16 | Healor Ltd. | Methods and pharmaceutical compositions for healing wounds |
US20040037828A1 (en) * | 2002-07-09 | 2004-02-26 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
US7306591B2 (en) | 2000-10-02 | 2007-12-11 | Novasys Medical, Inc. | Apparatus and methods for treating female urinary incontinence |
US7077841B2 (en) | 2001-03-26 | 2006-07-18 | Curon Medical, Inc. | Systems and methods employing a guidewire for positioning and stabilizing external instruments deployed within the body |
US6699243B2 (en) * | 2001-09-19 | 2004-03-02 | Curon Medical, Inc. | Devices, systems and methods for treating tissue regions of the body |
US20060155261A1 (en) | 2001-09-19 | 2006-07-13 | Curon Medical, Inc. | Systems and methods for treating tissue regions of the body |
US7615049B2 (en) * | 2001-09-19 | 2009-11-10 | Mederi Therapeutics, Inc. | Devices, systems and methods for treating tissue regions of the body |
US8235990B2 (en) | 2002-06-14 | 2012-08-07 | Ncontact Surgical, Inc. | Vacuum coagulation probes |
US6893442B2 (en) | 2002-06-14 | 2005-05-17 | Ablatrics, Inc. | Vacuum coagulation probe for atrial fibrillation treatment |
WO2004010934A2 (en) * | 2002-07-29 | 2004-02-05 | Rajiv Doshi | Methods for the use of neurotoxin in the treatment of urologic disorders |
US8021359B2 (en) | 2003-02-13 | 2011-09-20 | Coaptus Medical Corporation | Transseptal closure of a patent foramen ovale and other cardiac defects |
AU2004263009B2 (en) | 2003-08-07 | 2009-12-24 | Healor Ltd. | Pharmaceutical compositions and methods for accelerating wound healing |
US7150745B2 (en) | 2004-01-09 | 2006-12-19 | Barrx Medical, Inc. | Devices and methods for treatment of luminal tissue |
KR20060040550A (en) * | 2004-11-05 | 2006-05-10 | 마루이시세이야쿠가부시키가이샤 | Agent for promoting secretion of insulin-like growth factor-1 |
US7997278B2 (en) | 2005-11-23 | 2011-08-16 | Barrx Medical, Inc. | Precision ablating method |
US7959627B2 (en) | 2005-11-23 | 2011-06-14 | Barrx Medical, Inc. | Precision ablating device |
US8702694B2 (en) | 2005-11-23 | 2014-04-22 | Covidien Lp | Auto-aligning ablating device and method of use |
US20070142699A1 (en) * | 2005-12-16 | 2007-06-21 | Acoustx Corporation | Methods and implantable apparatuses for treating an esophageal disorder such as gastroesophageal reflux disease |
US20070142884A1 (en) * | 2005-12-16 | 2007-06-21 | Acoustx Corporation | Methods and apparatuses for treating an esophageal disorder such as gastroesophageal reflux disease |
US20080183237A1 (en) * | 2006-04-18 | 2008-07-31 | Electrocore, Inc. | Methods And Apparatus For Treating Ileus Condition Using Electrical Signals |
US20100057178A1 (en) * | 2006-04-18 | 2010-03-04 | Electrocore, Inc. | Methods and apparatus for spinal cord stimulation using expandable electrode |
US8641711B2 (en) | 2007-05-04 | 2014-02-04 | Covidien Lp | Method and apparatus for gastrointestinal tract ablation for treatment of obesity |
US8784338B2 (en) | 2007-06-22 | 2014-07-22 | Covidien Lp | Electrical means to normalize ablational energy transmission to a luminal tissue surface of varying size |
US8251992B2 (en) | 2007-07-06 | 2012-08-28 | Tyco Healthcare Group Lp | Method and apparatus for gastrointestinal tract ablation to achieve loss of persistent and/or recurrent excess body weight following a weight-loss operation |
CN102688092B (en) | 2007-07-06 | 2015-04-22 | 柯惠有限合伙公司 | Ablation in the gastrointestinal tract to achieve hemostasis and eradicate lesions with a propensity for bleeding |
US8646460B2 (en) | 2007-07-30 | 2014-02-11 | Covidien Lp | Cleaning device and methods |
CN101835486B (en) * | 2007-07-30 | 2012-12-12 | 希尔洛有限公司 | Pharmaceutical composition and related methods |
US8273012B2 (en) | 2007-07-30 | 2012-09-25 | Tyco Healthcare Group, Lp | Cleaning device and methods |
AU2010217213B2 (en) * | 2009-02-24 | 2013-05-23 | Healor Ltd. | Visfatin therapeutic agents for the treatment of acne and other conditions |
US10386990B2 (en) | 2009-09-22 | 2019-08-20 | Mederi Rf, Llc | Systems and methods for treating tissue with radiofrequency energy |
US9474565B2 (en) | 2009-09-22 | 2016-10-25 | Mederi Therapeutics, Inc. | Systems and methods for treating tissue with radiofrequency energy |
WO2011037621A2 (en) | 2009-09-22 | 2011-03-31 | Mederi Therapeutics Inc. | Systems and methods for controlling use and operation of a family of different treatment devices |
US9750563B2 (en) | 2009-09-22 | 2017-09-05 | Mederi Therapeutics, Inc. | Systems and methods for treating tissue with radiofrequency energy |
US9775664B2 (en) | 2009-09-22 | 2017-10-03 | Mederi Therapeutics, Inc. | Systems and methods for treating tissue with radiofrequency energy |
US10278774B2 (en) | 2011-03-18 | 2019-05-07 | Covidien Lp | Selectively expandable operative element support structure and methods of use |
US8403927B1 (en) | 2012-04-05 | 2013-03-26 | William Bruce Shingleton | Vasectomy devices and methods |
US9408662B2 (en) | 2012-05-07 | 2016-08-09 | Cook Medical Technologies Llc | Sphincterotome having expandable tines |
US9364277B2 (en) | 2012-12-13 | 2016-06-14 | Cook Medical Technologies Llc | RF energy controller and method for electrosurgical medical devices |
US9204921B2 (en) | 2012-12-13 | 2015-12-08 | Cook Medical Technologies Llc | RF energy controller and method for electrosurgical medical devices |
US11896823B2 (en) | 2017-04-04 | 2024-02-13 | Btl Healthcare Technologies A.S. | Method and device for pelvic floor tissue treatment |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5047027A (en) * | 1990-04-20 | 1991-09-10 | Everest Medical Corporation | Tumor resector |
US5522815A (en) * | 1993-03-29 | 1996-06-04 | Durgin, Jr.; Russell F. | Integrated catheter for diverse in situ tissue therapy |
US6790207B2 (en) * | 1998-06-04 | 2004-09-14 | Curon Medical, Inc. | Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract |
US6802841B2 (en) * | 1998-06-04 | 2004-10-12 | Curon Medical, Inc. | Systems and methods for applying a selected treatment agent into contact with tissue to treat sphincter dysfunction |
US7468060B2 (en) * | 1998-02-19 | 2008-12-23 | Respiratory Diagnostic, Inc. | Systems and methods for treating obesity and other gastrointestinal conditions |
Family Cites Families (162)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1798902A (en) | 1928-11-05 | 1931-03-31 | Edwin M Raney | Surgical instrument |
US3517128A (en) | 1968-02-08 | 1970-06-23 | James R Hines | Surgical expanding arm dilator |
US3901241A (en) | 1973-05-31 | 1975-08-26 | Al Corp Du | Disposable cryosurgical instrument |
DE2513868C2 (en) | 1974-04-01 | 1982-11-04 | Olympus Optical Co., Ltd., Tokyo | Bipolar electrodiathermy forceps |
US4196724A (en) | 1978-01-31 | 1980-04-08 | Frecker William H | Tongue locking device |
US4313968A (en) * | 1979-11-14 | 1982-02-02 | Ppg Industries, Inc. | Application of liquid coating material |
WO1981003271A1 (en) | 1980-05-13 | 1981-11-26 | American Hospital Supply Corp | A multipolar electrosurgical device |
JPS5755573A (en) | 1980-09-18 | 1982-04-02 | Olympus Optical Co Ltd | Cassette storing device |
US4565200A (en) | 1980-09-24 | 1986-01-21 | Cosman Eric R | Universal lesion and recording electrode system |
US4411266A (en) | 1980-09-24 | 1983-10-25 | Cosman Eric R | Thermocouple radio frequency lesion electrode |
US4313958A (en) | 1980-10-24 | 1982-02-02 | The Procter & Gamble Company | Method of producing analgesia |
US5370675A (en) | 1992-08-12 | 1994-12-06 | Vidamed, Inc. | Medical probe device and method |
US5385544A (en) | 1992-08-12 | 1995-01-31 | Vidamed, Inc. | BPH ablation method and apparatus |
US5421819A (en) | 1992-08-12 | 1995-06-06 | Vidamed, Inc. | Medical probe device |
US5435805A (en) | 1992-08-12 | 1995-07-25 | Vidamed, Inc. | Medical probe device with optical viewing capability |
US4601296A (en) | 1983-10-07 | 1986-07-22 | Yeda Research And Development Co., Ltd. | Hyperthermia apparatus |
US4705041A (en) | 1984-07-06 | 1987-11-10 | Kim Il G | Dilator for Sphincter of Oddi |
US5019075A (en) | 1984-10-24 | 1991-05-28 | The Beth Israel Hospital | Method and apparatus for angioplasty |
US5365926A (en) | 1986-11-14 | 1994-11-22 | Desai Jawahar M | Catheter for mapping and ablation and method therefor |
US5215103A (en) | 1986-11-14 | 1993-06-01 | Desai Jawahar M | Catheter for mapping and ablation and method therefor |
US5231995A (en) | 1986-11-14 | 1993-08-03 | Desai Jawahar M | Method for catheter mapping and ablation |
US4901737A (en) | 1987-04-13 | 1990-02-20 | Toone Kent J | Method and therapeutic apparatus for reducing snoring |
US4943290A (en) | 1987-06-23 | 1990-07-24 | Concept Inc. | Electrolyte purging electrode tip |
JPS6446056U (en) | 1987-09-17 | 1989-03-22 | ||
US5588432A (en) | 1988-03-21 | 1996-12-31 | Boston Scientific Corporation | Catheters for imaging, sensing electrical potentials, and ablating tissue |
US4907589A (en) | 1988-04-29 | 1990-03-13 | Cosman Eric R | Automatic over-temperature control apparatus for a therapeutic heating device |
DE3821544C2 (en) | 1988-06-25 | 1994-04-28 | H Prof Dr Med Just | Dilatation catheter |
US4947842A (en) | 1988-09-22 | 1990-08-14 | Medical Engineering And Development Institute, Inc. | Method and apparatus for treating tissue with first and second modalities |
US4939149A (en) | 1988-10-24 | 1990-07-03 | The United States Of America As Represented By The Department Of Health And Human Services | Resiniferatoxin and analogues thereof to cause sensory afferent C-fiber and thermoregulatory desensitization |
US4906203A (en) | 1988-10-24 | 1990-03-06 | General Motors Corporation | Electrical connector with shorting clip |
US4955377A (en) | 1988-10-28 | 1990-09-11 | Lennox Charles D | Device and method for heating tissue in a patient's body |
US4966597A (en) | 1988-11-04 | 1990-10-30 | Cosman Eric R | Thermometric cardiac tissue ablation electrode with ultra-sensitive temperature detection |
DE3838840C2 (en) | 1988-11-17 | 1997-02-20 | Leibinger Gmbh | High frequency coagulation device for surgical purposes |
CA1332905C (en) | 1989-03-10 | 1994-11-08 | John A. Murchie | Method and apparatus for treatment of snoring |
US5125928A (en) | 1989-04-13 | 1992-06-30 | Everest Medical Corporation | Ablation catheter with selectively deployable electrodes |
US5078717A (en) | 1989-04-13 | 1992-01-07 | Everest Medical Corporation | Ablation catheter with selectively deployable electrodes |
US4976711A (en) | 1989-04-13 | 1990-12-11 | Everest Medical Corporation | Ablation catheter with selectively deployable electrodes |
US5057107A (en) | 1989-04-13 | 1991-10-15 | Everest Medical Corporation | Ablation catheter with selectively deployable electrodes |
DE3915636C1 (en) | 1989-05-12 | 1990-04-26 | Sass, Wolfgang, Dr. | |
US5021450A (en) | 1989-05-30 | 1991-06-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof |
CA2017383A1 (en) * | 1989-06-08 | 1990-12-08 | Raymond R. Martodam | Use of vanilloids for the treatment of respiratory diseases or disorders |
US5084044A (en) | 1989-07-14 | 1992-01-28 | Ciron Corporation | Apparatus for endometrial ablation and method of using same |
CA2067110C (en) | 1989-09-08 | 2001-07-31 | John E. Abele | Physiologic low stress angioplasty |
US5035696A (en) | 1990-02-02 | 1991-07-30 | Everest Medical Corporation | Electrosurgical instrument for conducting endoscopic retrograde sphincterotomy |
US5205287A (en) | 1990-04-26 | 1993-04-27 | Hoechst Aktiengesellschaft | Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents |
US5122137A (en) | 1990-04-27 | 1992-06-16 | Boston Scientific Corporation | Temperature controlled rf coagulation |
US5236413B1 (en) | 1990-05-07 | 1996-06-18 | Andrew J Feiring | Method and apparatus for inducing the permeation of medication into internal tissue |
US5190540A (en) | 1990-06-08 | 1993-03-02 | Cardiovascular & Interventional Research Consultants, Inc. | Thermal balloon angioplasty |
US5083565A (en) | 1990-08-03 | 1992-01-28 | Everest Medical Corporation | Electrosurgical instrument for ablating endocardial tissue |
US5100423A (en) | 1990-08-21 | 1992-03-31 | Medical Engineering & Development Institute, Inc. | Ablation catheter |
CA2089739A1 (en) | 1990-09-14 | 1992-03-15 | John H. Burton | Combined hyperthermia and dilation catheter |
WO1992005752A1 (en) | 1990-10-03 | 1992-04-16 | Ernest Truffer | Snoring prevention device |
US5256138A (en) | 1990-10-04 | 1993-10-26 | The Birtcher Corporation | Electrosurgical handpiece incorporating blade and conductive gas functionality |
US5088979A (en) | 1990-10-11 | 1992-02-18 | Wilson-Cook Medical Inc. | Method for esophageal invagination and devices useful therein |
US5190541A (en) | 1990-10-17 | 1993-03-02 | Boston Scientific Corporation | Surgical instrument and method |
US5094233A (en) | 1991-01-11 | 1992-03-10 | Brennan Louis G | Turbinate sheath device |
US5368557A (en) | 1991-01-11 | 1994-11-29 | Baxter International Inc. | Ultrasonic ablation catheter device having multiple ultrasound transmission members |
US5370901A (en) | 1991-02-15 | 1994-12-06 | Bracco International B.V. | Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients |
US5156151A (en) | 1991-02-15 | 1992-10-20 | Cardiac Pathways Corporation | Endocardial mapping and ablation system and catheter probe |
US5465717A (en) | 1991-02-15 | 1995-11-14 | Cardiac Pathways Corporation | Apparatus and Method for ventricular mapping and ablation |
US5409453A (en) | 1992-08-12 | 1995-04-25 | Vidamed, Inc. | Steerable medical probe with stylets |
US5345936A (en) | 1991-02-15 | 1994-09-13 | Cardiac Pathways Corporation | Apparatus with basket assembly for endocardial mapping |
US5275610A (en) | 1991-05-13 | 1994-01-04 | Cook Incorporated | Surgical retractors and method of use |
AU1899292A (en) | 1991-05-24 | 1993-01-08 | Ep Technologies Inc | Combination monophasic action potential/ablation catheter and high-performance filter system |
US5383917A (en) | 1991-07-05 | 1995-01-24 | Jawahar M. Desai | Device and method for multi-phase radio-frequency ablation |
CA2071137A1 (en) | 1991-07-10 | 1993-01-11 | Clarence C. Lee | Composition and method for revitalizing scar tissue |
US5275608A (en) | 1991-10-16 | 1994-01-04 | Implemed, Inc. | Generic endoscopic instrument |
US5257451A (en) | 1991-11-08 | 1993-11-02 | Ep Technologies, Inc. | Method of making durable sleeve for enclosing a bendable electrode tip assembly |
US5363861A (en) | 1991-11-08 | 1994-11-15 | Ep Technologies, Inc. | Electrode tip assembly with variable resistance to bending |
AU3128593A (en) | 1991-11-08 | 1993-06-07 | Ep Technologies Inc | Radiofrequency ablation with phase sensitive power detection |
US5275162A (en) | 1991-11-08 | 1994-01-04 | Ep Technologies, Inc. | Valve mapping catheter |
DE69233091T2 (en) | 1991-11-08 | 2004-05-06 | Boston Scientific Ltd., St. Michael | ABLATION ELECTRODE WITH INSULATED TEMPERATURE MEASURING ELEMENT |
US5328467A (en) | 1991-11-08 | 1994-07-12 | Ep Technologies, Inc. | Catheter having a torque transmitting sleeve |
US5197964A (en) | 1991-11-12 | 1993-03-30 | Everest Medical Corporation | Bipolar instrument utilizing one stationary electrode and one movable electrode |
US5197963A (en) | 1991-12-02 | 1993-03-30 | Everest Medical Corporation | Electrosurgical instrument with extendable sheath for irrigation and aspiration |
US5263493A (en) | 1992-02-24 | 1993-11-23 | Boaz Avitall | Deflectable loop electrode array mapping and ablation catheter for cardiac chambers |
US5242441A (en) | 1992-02-24 | 1993-09-07 | Boaz Avitall | Deflectable catheter with rotatable tip electrode |
US5480644A (en) | 1992-02-28 | 1996-01-02 | Jsf Consultants Ltd. | Use of injectable biomaterials for the repair and augmentation of the anal sphincters |
US5281216A (en) | 1992-03-31 | 1994-01-25 | Valleylab, Inc. | Electrosurgical bipolar treating apparatus |
US5314466A (en) | 1992-04-13 | 1994-05-24 | Ep Technologies, Inc. | Articulated unidirectional microwave antenna systems for cardiac ablation |
US5281217A (en) | 1992-04-13 | 1994-01-25 | Ep Technologies, Inc. | Steerable antenna systems for cardiac ablation that minimize tissue damage and blood coagulation due to conductive heating patterns |
WO1993020768A1 (en) | 1992-04-13 | 1993-10-28 | Ep Technologies, Inc. | Steerable microwave antenna systems for cardiac ablation |
WO1993020886A1 (en) | 1992-04-13 | 1993-10-28 | Ep Technologies, Inc. | Articulated systems for cardiac ablation |
US5431914A (en) | 1992-04-17 | 1995-07-11 | Adekunle; Michael | Method of treating an internal condition by external application of capsaicin without the need for systemic absorption |
US5277201A (en) | 1992-05-01 | 1994-01-11 | Vesta Medical, Inc. | Endometrial ablation apparatus and method |
US5562720A (en) | 1992-05-01 | 1996-10-08 | Vesta Medical, Inc. | Bipolar/monopolar endometrial ablation device and method |
US5443470A (en) | 1992-05-01 | 1995-08-22 | Vesta Medical, Inc. | Method and apparatus for endometrial ablation |
US5281218A (en) | 1992-06-05 | 1994-01-25 | Cardiac Pathways Corporation | Catheter having needle electrode for radiofrequency ablation |
US5324284A (en) | 1992-06-05 | 1994-06-28 | Cardiac Pathways, Inc. | Endocardial mapping and ablation system utilizing a separately controlled ablation catheter and method |
US5254126A (en) | 1992-06-24 | 1993-10-19 | Ethicon, Inc. | Endoscopic suture punch |
WO1994002077A2 (en) | 1992-07-15 | 1994-02-03 | Angelase, Inc. | Ablation catheter system |
US5484400A (en) | 1992-08-12 | 1996-01-16 | Vidamed, Inc. | Dual channel RF delivery system |
US5470308A (en) | 1992-08-12 | 1995-11-28 | Vidamed, Inc. | Medical probe with biopsy stylet |
US5456662A (en) | 1993-02-02 | 1995-10-10 | Edwards; Stuart D. | Method for reducing snoring by RF ablation of the uvula |
US5556377A (en) | 1992-08-12 | 1996-09-17 | Vidamed, Inc. | Medical probe apparatus with laser and/or microwave monolithic integrated circuit probe |
US5486161A (en) | 1993-02-02 | 1996-01-23 | Zomed International | Medical probe device and method |
US5514131A (en) | 1992-08-12 | 1996-05-07 | Stuart D. Edwards | Method for the ablation treatment of the uvula |
US5672153A (en) | 1992-08-12 | 1997-09-30 | Vidamed, Inc. | Medical probe device and method |
US5309910A (en) | 1992-09-25 | 1994-05-10 | Ep Technologies, Inc. | Cardiac mapping and ablation systems |
US5313943A (en) | 1992-09-25 | 1994-05-24 | Ep Technologies, Inc. | Catheters and methods for performing cardiac diagnosis and treatment |
US5293869A (en) | 1992-09-25 | 1994-03-15 | Ep Technologies, Inc. | Cardiac probe with dynamic support for maintaining constant surface contact during heart systole and diastole |
US5401272A (en) | 1992-09-25 | 1995-03-28 | Envision Surgical Systems, Inc. | Multimodality probe with extendable bipolar electrodes |
US5471982A (en) | 1992-09-29 | 1995-12-05 | Ep Technologies, Inc. | Cardiac mapping and ablation systems |
US5334196A (en) | 1992-10-05 | 1994-08-02 | United States Surgical Corporation | Endoscopic fastener remover |
US5305696A (en) * | 1992-10-05 | 1994-04-26 | Mendenhall Robert Lamar | Process and system for treating contaminated particulate soil compositions |
US5415657A (en) | 1992-10-13 | 1995-05-16 | Taymor-Luria; Howard | Percutaneous vascular sealing method |
WO1994010924A1 (en) | 1992-11-13 | 1994-05-26 | American Cardiac Ablation Co., Inc. | Fluid cooled electrosurgical probe |
US5348554A (en) | 1992-12-01 | 1994-09-20 | Cardiac Pathways Corporation | Catheter for RF ablation with cooled electrode |
US5409483A (en) | 1993-01-22 | 1995-04-25 | Jeffrey H. Reese | Direct visualization surgical probe |
JPH08506259A (en) | 1993-02-02 | 1996-07-09 | ヴィーダメッド インコーポレイテッド | Transurethral needle excision device and method |
DE4303882C2 (en) | 1993-02-10 | 1995-02-09 | Kernforschungsz Karlsruhe | Combination instrument for separation and coagulation for minimally invasive surgery |
US5403311A (en) | 1993-03-29 | 1995-04-04 | Boston Scientific Corporation | Electro-coagulation and ablation and other electrotherapeutic treatments of body tissue |
US5365945A (en) | 1993-04-13 | 1994-11-22 | Halstrom Leonard W | Adjustable dental applicance for treatment of snoring and obstructive sleep apnea |
AU686173B2 (en) | 1993-06-10 | 1998-02-05 | Mir A. Imran | Transurethral radio frequency ablation apparatus |
US5860974A (en) | 1993-07-01 | 1999-01-19 | Boston Scientific Corporation | Heart ablation catheter with expandable electrode and method of coupling energy to an electrode on a catheter shaft |
DE4323585A1 (en) | 1993-07-14 | 1995-01-19 | Delma Elektro Med App | Bipolar high-frequency surgical instrument |
US5738096A (en) | 1993-07-20 | 1998-04-14 | Biosense, Inc. | Cardiac electromechanics |
US5433739A (en) | 1993-11-02 | 1995-07-18 | Sluijter; Menno E. | Method and apparatus for heating an intervertebral disc for relief of back pain |
US5458597A (en) | 1993-11-08 | 1995-10-17 | Zomed International | Device for treating cancer and non-malignant tumors and methods |
US5599345A (en) | 1993-11-08 | 1997-02-04 | Zomed International, Inc. | RF treatment apparatus |
US5472441A (en) | 1993-11-08 | 1995-12-05 | Zomed International | Device for treating cancer and non-malignant tumors and methods |
US5507743A (en) | 1993-11-08 | 1996-04-16 | Zomed International | Coiled RF electrode treatment apparatus |
US5536267A (en) | 1993-11-08 | 1996-07-16 | Zomed International | Multiple electrode ablation apparatus |
WO1995020345A1 (en) | 1994-01-28 | 1995-08-03 | Ep Technologies, Inc. | Minimizing blood contact in cardiac tissue measurements |
US5423812A (en) | 1994-01-31 | 1995-06-13 | Ellman; Alan G. | Electrosurgical stripping electrode for palatopharynx tissue |
US5458596A (en) | 1994-05-06 | 1995-10-17 | Dorsal Orthopedic Corporation | Method and apparatus for controlled contraction of soft tissue |
US6006755A (en) * | 1994-06-24 | 1999-12-28 | Edwards; Stuart D. | Method to detect and treat aberrant myoelectric activity |
US6044846A (en) * | 1994-06-24 | 2000-04-04 | Edwards; Stuart D. | Method to treat esophageal sphincters |
US5505730A (en) | 1994-06-24 | 1996-04-09 | Stuart D. Edwards | Thin layer ablation apparatus |
US6464689B1 (en) * | 1999-09-08 | 2002-10-15 | Curon Medical, Inc. | Graphical user interface for monitoring and controlling use of medical devices |
US6056744A (en) | 1994-06-24 | 2000-05-02 | Conway Stuart Medical, Inc. | Sphincter treatment apparatus |
US5823197A (en) | 1994-06-24 | 1998-10-20 | Somnus Medical Technologies, Inc. | Method for internal ablation of turbinates |
US5454782A (en) | 1994-08-11 | 1995-10-03 | Perkins; Rodney C. | Translumenal circumferential energy delivery device |
US5609151A (en) | 1994-09-08 | 1997-03-11 | Medtronic, Inc. | Method for R-F ablation |
US5558673A (en) | 1994-09-30 | 1996-09-24 | Vidamed, Inc. | Medical probe device and method having a flexible resilient tape stylet |
US5571116A (en) | 1994-10-02 | 1996-11-05 | United States Surgical Corporation | Non-invasive treatment of gastroesophageal reflux disease |
US5514130A (en) | 1994-10-11 | 1996-05-07 | Dorsal Med International | RF apparatus for controlled depth ablation of soft tissue |
US5588960A (en) | 1994-12-01 | 1996-12-31 | Vidamed, Inc. | Transurethral needle delivery device with cystoscope and method for treatment of urinary incontinence |
US5713891A (en) * | 1995-06-02 | 1998-02-03 | Children's Medical Center Corporation | Modified solder for delivery of bioactive substances and methods of use thereof |
US5709224A (en) | 1995-06-07 | 1998-01-20 | Radiotherapeutics Corporation | Method and device for permanent vessel occlusion |
US5702438A (en) | 1995-06-08 | 1997-12-30 | Avitall; Boaz | Expandable recording and ablation catheter system |
US6180658B1 (en) * | 1995-07-14 | 2001-01-30 | Medosan Ricerca S.R.L. | Method for counteracting blood platelet aggregation in a patient in need thereof |
US5624439A (en) | 1995-08-18 | 1997-04-29 | Somnus Medical Technologies, Inc. | Method and apparatus for treatment of air way obstructions |
US5840762A (en) | 1996-01-12 | 1998-11-24 | Genderm Corporation | Method for the treatment of cardiac arrhythmias and shortening of action potential duration |
US5830213A (en) | 1996-04-12 | 1998-11-03 | Ep Technologies, Inc. | Systems for heating and ablating tissue using multifunctional electrode structures |
US5871483A (en) | 1996-01-19 | 1999-02-16 | Ep Technologies, Inc. | Folding electrode structures |
US5836874A (en) | 1996-04-08 | 1998-11-17 | Ep Technologies, Inc. | Multi-function electrode structures for electrically analyzing and heating body tissue |
US6077257A (en) * | 1996-05-06 | 2000-06-20 | Vidacare, Inc. | Ablation of rectal and other internal body structures |
US6464697B1 (en) * | 1998-02-19 | 2002-10-15 | Curon Medical, Inc. | Stomach and adjoining tissue regions in the esophagus |
US6073052A (en) | 1996-11-15 | 2000-06-06 | Zelickson; Brian D. | Device and method for treatment of gastroesophageal reflux disease |
US5962532A (en) | 1997-03-13 | 1999-10-05 | Campbell; James N. | Therapeutic method with capsaicin and capsaicin analogues |
US6238872B1 (en) * | 1997-04-01 | 2001-05-29 | S.E.T.-Smart Endolumenal Technologies Ltd. | Targeted therapy to a biomedical device |
GB9711962D0 (en) * | 1997-06-10 | 1997-08-06 | Reckitt & Colmann Prod Ltd | Therapeutically active compositions |
EP1014957A4 (en) * | 1997-08-28 | 2004-01-28 | Afferon Corp | Urinary incontinence therapy |
US6440128B1 (en) | 1998-01-14 | 2002-08-27 | Curon Medical, Inc. | Actively cooled electrode assemblies for forming lesions to treat dysfunction in sphincters and adjoining tissue regions |
US6358245B1 (en) | 1998-02-19 | 2002-03-19 | Curon Medical, Inc. | Graphical user interface for association with an electrode structure deployed in contact with a tissue region |
US6156032A (en) | 1998-09-30 | 2000-12-05 | Scimed Life Systems, Inc. | Method for causing a stricture of a body passageway |
US6251064B1 (en) | 1998-12-11 | 2001-06-26 | Enteric Medical Technologies, Inc. | Method for creating valve-like mechanism in natural body passageway |
US6238335B1 (en) | 1998-12-11 | 2001-05-29 | Enteric Medical Technologies, Inc. | Method for treating gastroesophageal reflux disease and apparatus for use therewith |
US6425877B1 (en) * | 1999-04-02 | 2002-07-30 | Novasys Medical, Inc. | Treatment of tissue in the digestive circulatory respiratory urinary and reproductive systems |
US6409723B1 (en) * | 1999-04-02 | 2002-06-25 | Stuart D. Edwards | Treating body tissue by applying energy and substances |
US6358197B1 (en) | 1999-08-13 | 2002-03-19 | Enteric Medical Technologies, Inc. | Apparatus for forming implants in gastrointestinal tract and kit for use therewith |
-
2001
- 2001-11-26 US US09/994,375 patent/US6790207B2/en not_active Expired - Lifetime
-
2004
- 2004-08-05 US US10/912,268 patent/US7293563B2/en not_active Expired - Fee Related
-
2007
- 2007-10-02 US US11/906,457 patent/US8161976B2/en not_active Expired - Fee Related
-
2012
- 2012-04-24 US US13/454,842 patent/US20120209144A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5047027A (en) * | 1990-04-20 | 1991-09-10 | Everest Medical Corporation | Tumor resector |
US5522815A (en) * | 1993-03-29 | 1996-06-04 | Durgin, Jr.; Russell F. | Integrated catheter for diverse in situ tissue therapy |
US7468060B2 (en) * | 1998-02-19 | 2008-12-23 | Respiratory Diagnostic, Inc. | Systems and methods for treating obesity and other gastrointestinal conditions |
US6790207B2 (en) * | 1998-06-04 | 2004-09-14 | Curon Medical, Inc. | Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract |
US6802841B2 (en) * | 1998-06-04 | 2004-10-12 | Curon Medical, Inc. | Systems and methods for applying a selected treatment agent into contact with tissue to treat sphincter dysfunction |
US7458378B2 (en) * | 1998-06-04 | 2008-12-02 | Respiratory Diagnostics, Inc. | Systems methods for applying a selected treatment agent into contact with tissue to treat sphincter dysfunction |
Also Published As
Publication number | Publication date |
---|---|
US7293563B2 (en) | 2007-11-13 |
US8161976B2 (en) | 2012-04-24 |
US6790207B2 (en) | 2004-09-14 |
US20080033374A1 (en) | 2008-02-07 |
US20050010171A1 (en) | 2005-01-13 |
US20020082670A1 (en) | 2002-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8161976B2 (en) | Systems and methods for applying a selected treatment agent into contact with tissue | |
US6802841B2 (en) | Systems and methods for applying a selected treatment agent into contact with tissue to treat sphincter dysfunction | |
EP2095786B1 (en) | Systems for treating obesity and other gastrointestinal conditions | |
US11541239B2 (en) | Nerve stimulation for treatment of diseases and disorders | |
Sorkin et al. | Tumour necrosis factor-α induces ectopic activity in nociceptive primary afferent fibres | |
US7326207B2 (en) | Surgical weight control device | |
US6516223B2 (en) | Apparatus for electroporation mediated delivery for drugs and genes | |
US8634929B2 (en) | Method for treatment of neoplastic cells in the prostate of a patient | |
AU2016219949B2 (en) | Bioelectronic pharmaceuticals | |
Brekken et al. | Hyaluronidase reduces the interstitial fluid pressure in solid tumours in a non-linear concentration-dependent manner | |
US20110071468A1 (en) | Systems and methods for applying a selected treatment agent into contact with tissue to treat sphincter dysfunction | |
US20220211426A1 (en) | Catheters that deliver pulsed electrical field for targeted cellular ablation | |
Sakakibara et al. | Firing patterns of micturition-related neurons in the pontine storage centre in cats | |
Fung et al. | Electrical stimulation of pneumotaxic center: activation of fibers and neurons | |
Gdovin et al. | Roles of the pontine pneumotaxic and micturition centers in respiratory inhibition during bladder contractions | |
TRACEY et al. | Sommaire du brevet 2977224 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |